• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMartin Shkreli

Martin Shkreli Calls U.S. Lawmakers ‘Imbeciles’

By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
February 4, 2016, 1:19 PM ET
Controversial Former Pharmaceutical CEO Martin Shkreli Testifies On Oversight In Drug Market
WASHINGTON, DC - FEBRUARY 04: Martin Shkreli, former CEO of Turing Pharmaceuticals LLC., listens to questions during a House Oversight and Government Reform Committee hearing on Capitol Hill, February 4, 2016 in Washington, DC. Shkreli invoked his 5th Amendment right not to testify to the committee that is examining the prescription drug market. (Photo by Mark Wilson/Getty Images)Photograph by Mark Wilson via Getty Images

Martin Shkreli showed up in Washington today to attend a hearing of the U.S. House Committee on Oversight and Government Reform. Rather than provide answers as to why his former company, Turing Pharmaceuticals, jacked up the price of an off-patent drug called Daraprim by over 5,000%, he opted to invoke his Fifth Amendment right to not ” be a witness himself.”

“I intend to follow the advice of my counsel, not yours,” Shkreli told Rep. Trey Gowdy, a Republican from South Carolina.

That terse answer was a relative mouthful given Shkreli’s limited replies during his appearance at the hearing. However, that code of silence went out the window once he took to Twitter (TWTR). Shkreli used the public platform to first insult the lawmakers then justify his nonchalant appearance after smirking throughout the hearing.

Hard to accept that these imbeciles represent the people in our government.

— Martin Shkreli (e/acc) (@MartinShkreli) February 4, 2016

I had prior counsel produce a memo on facial expressions during congressional testimony if anyone wants to see it. Interesting precedence.

— Martin Shkreli (e/acc) (@MartinShkreli) February 4, 2016

Shkreli, who is no longer CEO of Turing but is still its largest shareholder, was subpoenaed and required to appear as a witness at Thursday’s hearing. Ahead of the hearing, Turing was also required to supply documents related to its pricing of Daraprim. According to excerpts from the nearly 250,000 pages of documents provided, Shkreli expected the payoff to be “huge” from the price increase, calling it a “handsome investment for all of us.” Shkreli didn’t comment on those statements to lawmakers—or on Twitter.

About the Author
By Laura Lorenzetti
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.